EP0612247A1 - Utilisation de composes de sulfonyle - Google Patents

Utilisation de composes de sulfonyle

Info

Publication number
EP0612247A1
EP0612247A1 EP92923587A EP92923587A EP0612247A1 EP 0612247 A1 EP0612247 A1 EP 0612247A1 EP 92923587 A EP92923587 A EP 92923587A EP 92923587 A EP92923587 A EP 92923587A EP 0612247 A1 EP0612247 A1 EP 0612247A1
Authority
EP
European Patent Office
Prior art keywords
compounds
methyl
formula
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92923587A
Other languages
German (de)
English (en)
Inventor
Dieter Flockerzi
Christian Schudt
Hermann Amschler
Rolf Beume
Richard Riedel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of EP0612247A1 publication Critical patent/EP0612247A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Definitions

  • the invention relates to the use of sulfonyl compounds for the manufacture of new drugs.
  • the invention relates to the use of compounds of the formula I.
  • R2 is hydrogen (H), 1-4C-alkyl or 1-4C-alkoxy
  • R3 is hydrogen (H), 1-4C-alkyl or 1-4C-alkoxy
  • R4 is hydrogen (H), methyl or methoxy
  • R5 is hydrogen (H) or 1-4C-alkyl
  • 1-4C-Alkyl stands for straight-chain or branched alkyl radicals with 1 to 4 carbon atoms. Examples include butyl, iso-butyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and especially methyl est.
  • 1-4C-Al oxy radicals contain, in addition to the oxygen atom, one of the above-mentioned I-4C-alkyl radicals.
  • the methoxy radical is preferred.
  • Halogen in the sense of the present invention is bromine, chlorine and fluorine.
  • substituted phenyl radicals R6 which may be mentioned are: 4-methylphenyl, 4-tert-butylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,5-dichloropheny and 4-hydroxyphenyl.
  • Suitable pharmacologically acceptable salts for compounds of the formula I are preferably all acid addition salts with inorganic acids customarily used in galenics. Suitable as such are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2- (4-hydroxybenzoyl) benzoic acid, butyric acid, maleinosalicylic acid ⁇ acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, e bonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, the acids in the salt production - depending on whether it is a one or polyacid acts and, depending on which salt is desired - be used in an e
  • proliferative, inflammatory and allergic skin diseases are mentioned as dermatoses.
  • the compounds of the formula I can be used for the prevention and treatment of the following skin diseases. The following are used: psoriasis vulgaris, toxic and allergic contact dermatitis, atopic dermatitis, seborrheic dermatitis, follicular and extensive pyoderma, endogenous and exogenous acne, rosacea and other proliferative, inflammatory and allergic skin diseases.
  • Another object of the invention is thus the use of compounds of formula I and their pharmacologically acceptable salts for the treatment of such individuals who are suffering from dermatoses.
  • the compounds of the formula I are used in particular in the form of those medicaments which are suitable for topical application.
  • suitable pharmaceutical formulations include, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions in which the active substance content is advantageously between 0.1 and 99%.
  • auxiliaries which are suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
  • solvents for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers or permeation promoters can be used.
  • R4 is hydrogen or methyl
  • R5 is hydrogen or 1-4C-alkyl
  • R6 denotes 1-4C-A1kyl, phenyl or substituted phenyl with a substituent from the group 1-4C-A1kyl, 1-4C-alkoxy and halogen, and their pharmacologically acceptable salts. Of particular note is the use of such in accordance with the invention
  • R4 is hydrogen or methyl
  • the radical -N (R5) SC R6 is in the 4-position on the phenyl radical bonded in the 6-position on the benzo-naphthyridine ring
  • R5 is hydrogen, methyl or ethyl
  • R6 is methyl, 4-methylphenyl, 4-methoxyphenyl or 4-fluorophenyl, and their pharmacologically acceptable salts.
  • the benzo-naphthyridine cycle has (at positions 4a and 10b) two centers of chirality.
  • the invention therefore includes all conceivable enantiomers and diastereomers as well as the racemates and mixtures thereof.
  • Preferred compounds of the formula I are those in which the hydrogen atoms in positions 4a and 10b are in the cis position.
  • the separation of the trans compounds from the (additionally diastereomeric) cis compounds is carried out - as is the separation of the (+) - and (-) - enantiomers - in a manner familiar to the person skilled in the art, e.g. as described in European patent application 247971.
  • the compounds of formula I and their salts are prepared by a process which is characterized in that a) Compounds of the formula II (see attached formula sheet), in which Rl, R2, R3, R4 and R5 have the meanings indicated above, with sulfonyl compounds of the formula III (see attached formula sheet), in which R6 has the meaning indicated above and X represents a suitable leaving group, um ⁇ , or that one
  • the reaction of the compounds II with the compounds III takes place in inert solvents in a manner known to the person skilled in the art for the production of sulfonates.
  • the leaving group X is preferably a halogen atom, in particular a chlorine atom.
  • the implementation is preferably carried out in the presence of an auxiliary base, e.g. an organic amine such as triethylamine or pyridine, or e.g. a carbonate, such as potassium carbonate or sodium carbonate.
  • the deprotonating agents that can be used are those agents for which the acidity of the proton on the nitrogen is high enough to achieve anion formation.
  • organometallic compounds such as, for example, butyl lithium
  • metal hydrides in particular sodium hydride, or alkali metal alcoholates, for example sodium methylate or potassium tert-butoxide, or Alihydroxide, such as sodium hydroxide or potassium hydroxide, or alkali carbonates, such as sodium carbonate mentioned.
  • the leaving group Y of the compounds IV is a group which is easily split off when Y-R5 is reacted with the deprotonated I, for example a halogen atom, such as chlorine, bromine or iodine, or the alkyl sulfate group.
  • the deprotonation and subsequent N-alkylation is carried out in inert, water-free solvents, such as are suitable for working with strong deprotonating agents, or in water-solvent mixtures, such as are used when working under phase transfer conditions.
  • inert, water-free solvents such as are suitable for working with strong deprotonating agents, or in water-solvent mixtures, such as are used when working under phase transfer conditions.
  • examples include open-chain or cyclic ethers, such as diethyl ether, doxane or tetrahydrofuran, or solvents such as DMF or DMSO.
  • water / solvent mixtures are the mixtures of water with chloroform, dichloromethane or benzene.
  • the reaction is preferably carried out under mild reaction conditions at temperatures around or below 0 ⁇ C.
  • cyclocondensation according to process variant c) is carried out in a manner known per se to the person skilled in the art according to Bisch! Er-Napieralski in the presence of a suitable condensing agent, such as, for example, polyphosphoric acid, phosphorus pentachloride, phosphorus pentoxide or preferably phosphorus oxychloride, in a suitable inert solvent, e.g.
  • a chlorinated hydrocarbon such as chloroform
  • a cyclic hydrocarbon such as toluene or xylene
  • another inert solvent such as acetonitrile
  • an excess of condensing agent preferably at elevated temperature, especially at Boiling temperature of the solvent or condensation agent used.
  • the compounds of the formula V are obtained in a manner known per se from the compounds VI and VII (see reaction scheme of the formula sheet) in which R 1, R 2, R 3, R 4, R 5 and R 6 have the meanings indicated above and Z is a suitable leaving group, for example represents a chlorine atom.
  • Compounds VI are e.g. known from DE-OS 21 23 328 or EP-A-247 971 or they can be prepared in an analogous manner.
  • the compounds VII are also known or can be prepared in a manner known to the person skilled in the art.
  • the trans compounds are separated from the cis compounds and the (+) and (-) enantiomers are advantageously separated at the stage of the preliminary and intermediate products prepared analogously to EP-A-247 971 .
  • the starting compound rac-cis-3- (3,4-dimethoxyphenyl) -l-methl-4- [4-methyl-3- (p-toluenesulfonamido) -benzamido] -piperidine is obtained by reacting 4, 6 g of 4-methyl-3- (p-toluenesulfonamido) -benzoic acid chloride with 3.0 g of rac-cis-4-amino-3- (3,4-dimethoxyphenyl) -l-methylpiperidine (produced in a manner analogous to that in DE -OS 21 23328 described procedure) and 4 ml of triethylamine in 50 ml of anhydrous dichloromethane. After shaking out with NaHCO 3 solution, drying the organic phase over sodium sulfate and concentrating, the residue is recrystallized in methanol. Yield: 4.2 g, mp 142-146 ° C.
  • the starting compound rac-cis-3- (3,4-dimethoxyphenyl) -l-methyl-4- [2- (p-toluenesulfonamido) -benzamido] -piperidine is obtained analogously to Example 3 from 2- (p-toluo! Sulfonamido) -benzoic acid chloride and the corresponding piperidine. Yield: 70%.
  • Example 2 The title compound is obtained analogously to Example 1 when p-methoxyphenylsulfonic acid chloride is used. Yield: 66%, mp. 210-217 ° C (crystallized as carbonate hydrate from methanol).
  • the title compound is obtained analogously to Example 3 if rac-cis- -3- (3,4-dimethoxyphenyl) -1-methyl-4 - [(4-p-methoxyphenylsulfonamido) benzamido] piperidine is cyclocondensed.
  • This starting compound is obtained Analogously to Example 3, if 4- (p-methoxyphenylsulfonamido) benzoic acid chloride is used.
  • Example 3 Analogously to Example 3, the title compound is obtained when rac-cis-3- (3,4-dimethoxyphenyl) -1-methyl-4 - [(p-fluorophenylsulfonamido) benzamido] piperidine is used. Yield: 69%, mp 163-165 ⁇ C.
  • the starting compound is obtainable analogously to Example 3 from 4- (p-fluorophenylsulfonamido) benzoic acid chloride. Yield: 60%, m.p. 108-113'C.
  • Example 3 Analogously to Example 3, the title compound is obtained from rac-cis-3- (3,4-dimethoxyphenyl) -1-methyl-4 - [(p-toluenesulfone-N-methylamido) benzamido] piperidine; Yield: 53%, mp. 157-158 ⁇ C (from methanol / ether).
  • the starting compound is obtainable analogously to Example 3 from 4- (p-toluenesulfone-N-methylamido) benzoic acid chloride.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de composés répondant à la formule (I), dans laquelle les substituants ont les propriétés énoncées dans la description, ainsi que de leurs sels compatibles sur le plan pharmacologique, pour fabriquer des médicaments destinés au traitement de dermatoses.
EP92923587A 1991-11-15 1992-11-11 Utilisation de composes de sulfonyle Withdrawn EP0612247A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH33344/91 1991-11-15
CH334491 1991-11-15
PCT/EP1992/002583 WO1993009780A1 (fr) 1991-11-15 1992-11-11 Utilisation de composes de sulfonyle

Publications (1)

Publication Number Publication Date
EP0612247A1 true EP0612247A1 (fr) 1994-08-31

Family

ID=4253939

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92923587A Withdrawn EP0612247A1 (fr) 1991-11-15 1992-11-11 Utilisation de composes de sulfonyle

Country Status (2)

Country Link
EP (1) EP0612247A1 (fr)
WO (1) WO1993009780A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8106598A (en) * 1997-06-03 1998-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
JP2004285038A (ja) * 2002-05-31 2004-10-14 Takeda Chem Ind Ltd ピペリジン誘導体、その製造法および用途
NZ537330A (en) 2002-05-31 2007-04-27 Takeda Chemical Industries Ltd Piperidine derivative, process for producing the same, and use
CA2566387A1 (fr) 2004-05-12 2005-12-01 Chemocentryx, Inc. Sulfonamides aryle
US7718683B2 (en) 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
ATE496905T1 (de) 2006-07-14 2011-02-15 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) * 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
EP0247971A3 (fr) * 1986-05-29 1990-01-17 Sandoz Ag Compositions pharmaceutiques contenant de la cis-6-(4-acétanilido)-8,9-diméthoxy-2-méthyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphtyridine et son utilisation
MY105344A (en) * 1990-05-16 1994-09-30 Byk Gulden Lomberg Chemische Fabrik New sulphonyl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9309780A1 *

Also Published As

Publication number Publication date
WO1993009780A1 (fr) 1993-05-27

Similar Documents

Publication Publication Date Title
EP0528922B1 (fr) Nouveaux composes de sulfonyle
DE3026201C2 (fr)
DE3707651A1 (de) Bis-naphthalimide, ihre herstellung und verwendung
DE68922478T2 (de) Pyrazoloisoquinoline-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
EP0299470A1 (fr) Imidazo[1,2-a]pyridines
EP0705820A1 (fr) Dérivés de 6-amino-acide nicotinique utile comme activateurs canaux potassiques
DE69830860T2 (de) N-Alkylierte Ureide
DE19501482A1 (de) 2,9-disubstituierte Purin-6-one
DE2505239C2 (fr)
WO1993009780A1 (fr) Utilisation de composes de sulfonyle
EP0968162A1 (fr) Phenyles substitues par 5-hydroxy-alkyle et leur utilisation dans des medicaments pour traiter l'arteriosclerose et l'hyperlipoproteinemie
EP0705830A1 (fr) Produits 2,3-cycliques de condensation de 1,4-dihydropyridine utile
EP0973744A1 (fr) Pyridines substituees par 2-amino s'utilisant pour traiter l'arteriosclerose et l'hyperlipoproteinemie
EP0225522A1 (fr) Imidazopyridazine-alkènecarboxamides, leur procédé de préparation, produits intermédiaires et leur préparation
DE2841126C2 (fr)
EP0173933A1 (fr) Dérivés de la 1,6-naphthyridine, procédé pour leur préparation et médicaments les contenant
DE2346466A1 (de) Neue pyrazolopyridobenzodiazepinone mit ihren salzen
DE2943286C2 (fr)
EP0873315B1 (fr) Derives de phenanthridine, procedes permettant de les preparer et medicaments contenant des phenanthridines
EP0004260B1 (fr) Dérivés quinolizidiniques et indolizidiniques substitués, leur procédé de préparation et médicaments les contenant
EP0014996B1 (fr) Spiro-amidines hétérocycliques, leurs stéréoisomères et isomères optiques, procédés pour leur préparation et médicaments les contenant
EP0180833A1 (fr) Dérivés de la 4-oxopyrido[2,3-d]pyrimidine, procédé pour leur préparation et médicaments les contenant
DE3718570A1 (de) Benzo- und thieno-3,4-dihydro-1- pyridinylessigsaeurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE2512974A1 (de) Neue sulfonyl-, sulfinyl- und sulfenylderivate von 1h-pyrazol(3,4-b) pyridinen
EP0770083A1 (fr) DERIVES DE PYRIDO[3,2,1-i,j][3,1]BENZOXAZINE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980603